SHEET 1 OF 3

/PF	<del></del>			ATTORNEY'S DKT NO. 012712-502		APPLICATION NO. 09/019,441		
	O INFORMATION DISCLOSURE				APPLICANT RECEIVE			
JUL 3 0 1998	CITATION			Mitchell E. REFF e	t al	GROUP	TVE	O
Ek. av	PTO-1449			February 5, 1998		1642	1 199 <sub>8</sub>	
GIRADEN		<u> </u>	S. PATENT DO	OGUMENTIS -			P 100 FILING	70
EXAMINER'S INITIALS	PATENT NO.	DATE		NAME	CLASS	SUBCLASS	FILING	
100	5,648,260	7/15/97	Winter et al					
WO	5,635,600	6/3/97	Fanger et al					
ms	5,585,089	12/17/96	Queen et al					
140	5,543,144	8/6/96	Chang					
	5,348,876	9/20/94	Michaelsen e	et al				
		FOR	EIGN PATENT	DOCUMENTS	T =	T	T	ation.
EXAMINER'S INITIALS	PATENT NO.	DATE	C	OUNTRY	CLASS	SUBCLASS	Transla Yes	No
MO	WO 88/06891	9/22 <b>/</b> 88	PCT					
1000								
	OTHER DOC	UMENTS (In	cluding Autho	r, Title, Date, Pert	tinent Pag	jes, Etc.)		
	Immunet: 76:6	6 <del>2-667, 1</del> 99	92	uble CD23-fragme				
NO	Pène et al, "Inte	Pène et al, "Interleukin 5 enhances interleukin 4-induced IgE production of normal human B cells", Eur. J. Immunol., 18:929-935, 1988						
M	Sarfati et al. "Ir	vitro synth	esis of IgE by	human lymphocyt	es", imm	unol., 53:197	7-205 1	984
NA()	Saxon et al, "In	hibition of h	uman IgE prod secretedcha	duction via Fc₀R-II iins", J. Immunol.,	stimulation 147(11)	on results fro :4000-4006,	m a 1991	
W	Sherr et al, "Bir Synthesis", J. I	nding the lov	v affinity Fc <sub>€</sub> R	on B cells suppres	sses ongo	oing human l	gE 	
MO	Bonnefoy et al,	"A new role	e for CD23 in i	inflammation", Imr	nunol. To	oday, 17(9):4	18-420	), 
MO	Bonnefoy et al.	, "Inhibition o	of human inter	leukin 4-induced l J. Immunol., 20:	gE syntho 139-144,	esis by a sub 1990	set of a	inti-
MA	Angal et al, "A	single amino	o acid substitu	ition abolishes the 30(1):105-108, 19	heteroge	eneity of chim	neric mo	ouse/
M	Urlaub et al, "E	ffect of gam	nma rays at th	e dihydrofolate rec cs, 12(6):555-566	ductase lo	ocus: deletio	ns and	
mo	D'Ambrosio et	al, "Recruitr	nent and Activ	vation of PTP1C in	Negative	e Regulation	of Antiq	gen 
M	Man Sung Co	et al. "Huma	nized anti-lew	is Y antibodies: ir Can. Res., 56:1118	n vitro pro	operties and 1996		
MO	Ono et al, "Del Cell, 90:293-3	etion of SHI	P or SHP-1 rev	veals two distinct	pathway	s for inhibitor	y signa	ling",
EXAMINER			10-1	DATE CONSIDERI	ED 9/1	6199		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 2 OF 3

OF		ATTORNEY'S DKT NO.	APPLICATION NO.					
	RMATION DISCLOSURE	012712-502 APPLICANT	GROUG ROLLS					
JUL 3 0 19	RIMATION DISCLOSURE  STO 1449	Mitchell E. REFF et al	GROUP O / /Vun					
700	PTO-1449	February 5, 1998	1642					
WOULD THANK	OUTHER DOCUMENTS (Including Author	, Title, Date, Perlinent Pag	193, <b>3</b> 10.) (100)					
NA	Parren et al, "Characterization of IgG FcR-mouse and human anti-CD3 handles	", J. Immunol., 148(3):695	-701, 1992					
NO	Steplewski et al, "Biological activity of human-mouse IgG1, IgG2, IgG3 and IgG4 chimeric monoclonal antibodies (1988) Specificity", Proc. Natl. Acad. Sci., 85(13):4852-4856, 1988							
Ma	Lund et al, "Human FcγRI and FcγRII interact with distinct but overlapping sites on human lgG.", J. Immunol., 147(8):2657-2662, 1991							
W	Man Sung Co et al, "Chimeric and human antigen", J. Immunol., 148(3):1149-1154	1 9 9 >						
MO	Parren et al, "Characterization of IgG FcR-mouse and human anti-CD3 Mantibodies",	mediated proliferation of r J. Immunol., 148(3):695-	numan T cells induced by 701, 1992					
mo	Wakai et al, "Anti-CD23 monoclonal antibody modulating capacities forproduction", H	oodies: comparisons of epit lybridoma, 12(1):25-43, 1	993					
	Shakib et al, "A study of the interrelations	ship between circulating Ig ol. et Immunopathol., 21(1	G subclass anti-lgŁ ):20-24, 1993					
2	Spiegelberg, "Fc Receptors for IgE and In	terleukin-4 induced IgE and	i IgG4 Secretion", J.					
au	Maliszewski, "Induction of B cell activities by interleukin 4 is inhibited by a receptor-specific monoclonal antibody in vitro", Eur. J. Immunol., 20:1735-1740, 1990							
un	Yanagihara et al, "Suppression of IgE production by IPD-1151T (Suplatast Tosilate), a new dimethylsulfonium agent: (1) regulationresponse", Japan J. Pharmacol., 61:23-30 (1993)							
in	Hjulström, "No role of interleukin-4 in CD antibody response in vivo", Eur. J. Immur	23/lgE-mediated enhancen nol., 25:1469-1472, 1995	nent of the murine					
MO	Escura et al, "Regulation and targeting of antibodies", Immunol., 86:343-350, (199	T-cell immune responses	by IgE and IgG					
(LD	Bonnefoy et al, "Production and characte human lymphocyte low affinity receptor	rization of a monoclonal a	970-2976, 1967					
Non	Gustavsson et al, "CD23/lgE-mediated re J. Immunol., 152(10):4793-4800, 1994	gulation of the specific an	tibody response in vivo",					
140	Yanigihara et al, "Éstablishment of sensit IgE-binding factor (soluble CD23), Int. An	ive radioimmunoassay for	the detection of human 8:189-199, 1992					
140	Flores-Romo et al, "Inhibition of an in viv CD23", Science, 261:1038-1041, 1993	o antigen-specific IgE resp	onse to antibodies to					
M	Luo et al, "Cross-linking of CD23 antiger prevents B lymphocite proliferation and of	by its natural ligand (IgE)	or by anti-CD23 antibody 22-2129, 1991					
NO	Pène et al, "IgE production by normal hu suppressed by interferons $\gamma$ and $\alpha$ $E_2$ "	man lymphocites is induce	d by interleukin 4 and					
M	Sarfati et al, "Possible role of human lym fragments in the in vitro synthesis of human	phocyte receptor for IgE (	CD23) or its soluble					
MED	Henchoz-Lecoanet et al, "The Epstein-Babinding and interleukin-4-induced IgE and	rr virus-binding site on CD	21 is involved in CD23					
NO	Bonnefoy et al, "Receptors for IgE", Cur.	Oninion in Immunol., 5:94	14-949, 1993 <u> </u>					
EXAMINER		DATE CONSIDERED	99					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 3 OF 3

_						No.		<u> </u>	늑			
	VIRECT	RMATION	DISCLOS	ATTORNEY'S DKT NO.  012712-502  APPLICANT  APPLICATION NO.  09/015-41-11/50								
	10.	CITATION				et al	JUL 3 1 1998					
:	JUL 3 0 199	98 PTO-1449			FILING DATE February 5, 199	8	GREENOUP 1800					
	Ten.		er da v a v a v a	S. PATENT DO	OCUMENTS				*			
	EXAMINER 5						CHBC! ACC	FILING DAT	Έ			
	INITIALS	PATENT NO.	DATE		NAME	CLASS	SUBCLASS		$\dashv$			
						<del> </del>	<del> </del>					
			1300 500 1000 1000		1907 - 1907 - 1907 - 1907 - 1907 - 1907 - 1907 - 1907 - 1907 - 1907 - 1907 - 1907 - 1907 - 1907 - 1907 - 1907		X X X X X X X X X X X X X X X X X X X		- Jan 1			
			FORE	IGN PATENT	DOCUMENTS		1	-	Ž			
	EXAMINER'S INITIALS	PATENT NO.	DATE	cc	DUNTRY	CLASS	SUBCLASS	Translation Yes No				
	HALLIMES		25									
		-	<del>  </del>			<del>                                     </del>						
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
	Pène et al, "Modulation of IL-4-induced human IgE production in vitro by IFN-γ and IL-5: the role of soluble CD23 (s-CD23)", J. Cell. Biochem., 39:253-264 (1989)											
11, 3 6	Bennefoy et al, "Regulation of IgE synthesis by GD23/GD21 interaction", Int. Arch. Allergy											
· ' ' '	/ Immunol.; 107:40*42, 1995											
·	MO	Aubry et al, "CD21 is a ligand for CD23 and regulater IgE production", Nature, 358:505-507, 1992										
	NUD	Grosjean et al, antigen by lym	Grosjean et al, "CD23/CD21 interaction is required for presentation of soluble protein antigen by lymphoblastoid B cellclones", Eur. J. Immunol., 24:2982-2986, 1994									
•	Carl	Nambu et al, "Functional significance of CD23- on CD23-transfected Th2 clone", Immunol. Letters, 44:163-167, 1995										
	COM	Burton et al, "Human Antibody Effector Function", Adv. Immunol., 51:1-84, 1992										
									_			
		<del> </del>										
		<del> </del>							_			
									_			
									_			
								-				
									_			
	<b></b>	1										
		<del> </del>		<del></del>		·						
	EXAMINER	Marian	_ ^		DATE CONSIDER	RED						
		11/10 man	~~ M	<i>─</i> ✓/	911	6149						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 1 OF 3

			*********			SHE	<u> </u>	<u> </u>	
-INIEC	DEMATION DICCLOSURE			ATTORNEY'S DKT NO. 012712-502		APPLICATION NO. 09/019,441			
TP TIME	RMATION DISCLOSURE CITATION			APPLICANT Mitchell E. Reff et al.					
4009	PTO-1449			FILING DATE	t ai.	GROUP			
UL 0 6 1998 or				February 5, 1998	3	1642			
		. U.S.	PATENT D	OCUMENTS					
LEXAMINER'S	DATENT NO	DATE		NAME	CI ACC	SUPPLIA SO	FILING	DATE	
INITIALS	PATENT NO. 4,940,782	07/10/90	Rup et al	NAME	CLASS	SUBCLASS			
NO P	1,010,702		- Indp of an	•	-				
	a de la companya de l	 	 N_PATENT	DOCUMENTS					
EXAMINER'S	•						Trans	lation	
INITIALS	PATENT NO.	DATE	<del>                                     </del>	COUNTRY	CLASS	SUBCLASS	Yes	No	
<del></del>	WO 89/00138	01/12/89	Internatio	nal					
	<del>WO-96/12741</del>	05/02/96	Internatio	nnal	<del> </del>				
wo	WO 87/07302	12/03/87	de Consulta	grav wo					
				W W O	<del></del>			-	
-									
#1. pt.	OTHER DOCUM	IENTS (Includ	ling Author	r, Title, Date, Pert	inent Pag	es: Etc.)			
	Rector et al., Imn								
	1.0000. 00 0.0, 1.11.	,	7-100-(10	007		<u>.</u>			
	-Seumura-et-al.,J	Immunol 1	37: 1214-	1220 (1986)			h		
		1		and the second s					
<u> </u>	Noro et al., J. Im	munol <del>., 137։</del> -	1-258-1-260	3-(-1-986)	JI	JE 0 8 1998			
					<u> </u>	و او		•	
MO .	Bonnefoy et al.,	J. Immunol., 1	38: 2970-	2978 (1987)	<u> </u>	PHYS CONT	T.F.F		
MO	Flores-Romo et al	., Science, 26	51: 1038-1	046 (1993)					
1110									
MO	Sherr et al., J. Im	munol., 142:	481-489 (	1989)					
mo	Dana at al. Dras	Not Acad C	·-: 1104 1	DE. 6000 6004 /	1000)				
	Pene et al., Proc.	Nati. Acad. S	oci., USA,	65. 0660-0664 <u>(</u>	1900)	<del>.</del>			
<u></u>	Bonnefoy et al., E	Fur J Immun	ol 20: 139	-144 (1990)					
	Bormordy of un, t	tar. o. minar	01 20: 100	144 (1000)					
mo	Sarfati et al., J. li	mmunol 141:	2195-219	9 (1988)					
	*			<u> </u>					
MA	Wakai et al., Hyb	ridoma 12: 25	5-43 (1993	3)					
			<del></del>			···			
	Yu et al., Nature	369: <del>-</del> 753 <del>-</del> 756	5=(4994) <del></del>						
		<u>-</u>					****		
EXAMINER	200 =	200	_ D	ATE CONSIDERE	D				
H	Mariane	. Hi 12	_ /	911	6199				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.

							:1 <u>Z</u> UF <u>3</u>	
NEORMATION DISCLOSURE				ATTORNEY'S DKT NO. APPLICATION 012712-353 08/803,085			VO.	
UL 0 6 1998	<u>'</u>			APPLICANT Mitchell E. Reff et al.				
MF 0 9 1930				FILING DATE February 20, 1997		GROUP ART UNIT		
Capane 197	PTO-144	Charles Allenant	1642					
EXAMINER'S		0.0.1	ALCHIND	CUMENTS			FILING DATE	
INITIALS	PATENT NO.	DATE	•	NAME	CLASS	SUBCLASS		
				<del></del>				
		FOREIGN	PATENT	DOCUMENTS	<u> </u>	ı		
EXAMINER'S INITIALS	PATENT NO.	DATE		COUNTRY	CLASS	SUBCLASS	Translation Yes No	
	OTHER DOCUM	IENTS (Includir	ng Author	, Title, Date, Pert	inent Pag	es, Etc.)		
MO	Saxon et al., J. In	nmunol., 147:	4000-400	06 (1991)				
90	D'Ambrosi <b>O</b> st al	Caianas 269	. 202 20	7 /1005\		The face to	* 6 8 6 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	
imo	D'Ambrosi <b></b> et al.	, Science, 200	5: 293-29	/ (1995)		\$ 9 5 m te		
W	Leconant et al., Immunol., 88: 35-39 (1996) JUL 0 8 1002							
	Large than 1 of Cont / Deliver							
	Bonnefey et al., I	nt: Amer. Aller	rgy Immur	101., 107. 40-42	(1995)	SEDVICE	CENTER	
w	Aubry et al., Natu	ıre, 358: 505-	507 6 19	192-)				
	-Aubry et al:; Imm	<b>⊎ก</b> оl- <sub>77=</sub> 5:∞944=1	9497(199)	3)				
	Bonnefoy et al., (	Surr. Opin. Eur	. J. Immu	nol24: 2982-29	988-(1994	1)		
140	Nambu et al., Imn	nunol. Lett., 4	4: 163-16	7 (1995)				
mo	Conforti et al. 1		7 20E (10	94)				
I NOW	Sarfati et al., Imm	iunoi., 53: 19.	/-205 (19	04)		**		
140	Pene et al., J. Ce	Il Biochem., 39	9: 253-26	9 (1989)				
	Pene et al., J. hm	munol., 18: 92	29-935-(1:	988)	The same and			
		<del></del>					-	
		<u></u>			<del>"</del>			
EXAMINER	mana	me Dis	D	ATE CONSIDERE	D 16199			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET <u>3</u> OF <u>3</u>

D I B ÍNEC	DRMATION D		RE	ATTORNEY'S DKT NO. APPLICATION NO. 012712-353 08/803,085  APPLICANT						
L 0 6 1998 53	CITATIO PTO-1449			Mitchell E. Reff et al.  FILING DATE GROUP ART UNIT February 20, 1997 1642						
		2 m	PATENT D							
EXAMINER'S INITIALS	PATENT NO.	DATE		NAME	CLASS	SUBCLASS	FILING D	)ATE		
		FOREIGN	N PATENT	DOCUMENTS	<u> </u>					
EXAMINER'S INITIALS	PATENT NO.	DATE		COUNTRY	CLASS	SUBCLASS	Translat Yes	tion No		
				<u> </u>	+	<del> </del>				
	OTHER DOCUM	L L IENTS (Includi	ing Author	r, Title, Date, Per	 rtinent Pag	es, Etc.)				
	Saxon et al., J. Cl	lin. Immunol. /	Allergy, 80	o (3 pt 1) 333-37	44 (1990)					
MO	Sarfati et al., Imm	nunol., 76: 66:	2-667 (19	92)						
MO	Angal et al., Mol. Immunol., 30: 105-108 (1993)									
	Hassner and Saxo	<del>ച, J. Immuno</del> i	<del>1., 132. 2</del> (	344 (1984)						
	Garroll-et-al., JIn	nmunok-Meth	ods-89+6	<del>1-(1986)</del>		Service of the servic				
	Boerner et al., J. I	tmmunol., 147	<del>7: 86 (19</del> 9	<del>)   )                                  </del>		ENTER				
		i			 	8 7998				
					f.,	CERTE				
EXAMINER	Maria	inne Dil	20	ATE CONSIDERE	ED (-/9a					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.